1. Generics Bulletin
  2. >>Legal & IP

Fresenius Kabi Faces Decade Wait On US Cinvanti Generic

Novel Formulation For Chemotherapy-Induced Nausea And Vomiting Stands Strong

 
• By Dean Rudge

Fresenius Kabi was unable to persuade a US court that its proposed generic version of Heron Therapeutics’ Cinvanti (aprepitant) injectable emulsion for chemotherapy-induced nausea and vomiting would not infringe a pair of patents stretching into the next decade.

US flag gavel (Stocksnapper/Alamy Stock Photo)
Shutterstock • Source: Shutterstock (Alamy Stock Photo)

Fresenius Kabi looks set to wait until the middle of the next decade to launch its proposed US generic version of Heron Therapeutics’ Cinvanti (aprepitant) injectable emulsion for chemotherapy-induced nausea and vomiting, after falling to the originator in patent-infringement proceedings.

The US District Court for the District of Delaware has held that Kabi’s aprepitant abbreviated new drug application product infringes...

Welcome to Generics Bulletin

Create an account to read this article

Already a subscriber?

More from Legal & IP

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By Dave Wallace

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 
• By Urtė Fultinavičiūtė

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By Dean Rudge

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

More from Generics Bulletin

Adalvo Changes Hands As EQT Takes Control

 
• By Dave Wallace

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 
• By Urtė Fultinavičiūtė

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.